Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy.
Localized proton MR spectroscopy was used to identify phenylalanine (PHE) and to quantitate its cerebral concentration in patients with type I phenylketonuria (PKU). Data acquisition was optimized for the detection of low-concentration metabolites, using a short TE (20 ms) double Hahn-echo localization sequence for large volumes within the head coil and for smaller volumes using a surface coil. Previously described methods to quantitate localized MR spectra were extended to cover the case of low-concentration metabolites, unevenly distributed in three brain compartments and measured in difference spectra only. PHE content was determined in difference spectra of four PKU patients with respect to normals and in one patient before and after an oral load of L-PHE. PHE concentrations of 0.3 to 0.6 mmol/kg brain tissue were obtained, resulting in a concentration gradient for PHE between blood and brain tissue of 2.4 to 3.0. No significant changes were found for the abundant metabolites in gray or white matter. Previously reported MRI changes were confirmed to be due to increased cerebro-spinal-fluid-like spaces.
Kreis
R
R
Department of MR Spectroscopy and Methodology, University of Berne, Switzerland.
Pietz
J
J
Penzien
J
J
Herschkowitz
N
N
Boesch
C
C
D000328:Adult; D001923:Brain Chemistry; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D010649:Phenylalanine / Q000032:analysis* / Q000302:isolation & purification*; D010661:Phenylketonurias / Q000378:metabolism*
D010649:Phenylalanine